January 21, 2014
ForeverGreen’s PowerStrips Could Be a Game-Changer
Direct marketing firms tend to sell a broad line of products as part of their business models, in the hope of developing a signature personal care product with brand recognition with which to take revenue to a whole new level. Utah-based ForeverGreen Worldwide, Corp. (OTCQB – FVRG) may have found this highly efficacious signature product with its PowerStrips line, which along with its FG Xpress segment, was pre-launched a year ago. Given the broad popularity and impressive sales growth during the pre-launch phase last year, the Company plans to make the product widely available across the globe in 2014.
In anticipation of the full-scale launch, the company recently added powerful industry leaders to the executive team which not only helps validate the uniqueness of the FDA listed product, but will substantially aid in enhancing the visibility, distribution and global footprint of the product. If, as management expects, broad adoption and sales of PowerStrips occur, it could put ForeverGreen in the top tier of the direct marketing arena.
PowerStrips combine a proprietary blend of ancient herbs, minerals and elements into a patented and proprietary effortless product that is applied topically. Once applied, the technology uses muscle and tissue to activate and boost energy simultaneously in areas of pain and discomfort and at a cellular level, bringing rejuvenation to the body. With 1.5 billion people suffering from chronic pain, this product is a potential game changer as it has a Class 1 medical device listing by the FDA, which is a huge differentiator in the market as compared to other, similar products sold today.
Each topically applied PowerStrip has two layers. The outer layer contains elemental Germanium. The inner or adhesive layer contains a proprietary blend of: Fermented Korean Red Ginseng, Silver and (Alpha-c CMPTM) Marine Phytoplankton. The unique ginseng contains Saponin which is an herb that is not consumed orally due to certain properties that in tests have not assimilated well through oral consumption despite its healing properties. Although specific efficacy data is limited, this herb has demonstrated to be effective in topical form. Testimonials from users of all ages are diverse and very positive. The strips are designed for use every 2 days and a 1-month pack of 15 strips costs $69.95.
Given that sales of PowerStrips alone approached $12 million in 2013 during the pre-launch phase, it is easy to see why sales are expected to escalate substantially in 2014. Moreover, since ForeverGreen management has recently provided Wall Street with monthly sales updates, investors can monitor overall progress and sales success rates, thus providing a healthy dose of comfort in the stock’s future, just like PowerStrips themselves.
You Might Also Like
Senior Analyst: Robert Goldman
This Opportunity Research Micro Cap Hot Topics article was prepared for informational purposes only.
Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research and Goldman Opportunity Research. The Select format reflects the Firm’s internally generated stock ideas along with economic and stock market outlooks. Opportunity Research reports, updates and Microcap Hot Topics articles reflect sponsored (paid) research but can also include non-sponsored micro cap research ideas that typically carry greater risks than those stocks covered in the Select Research category. It is important to note that while we may track performance separately, we utilize many of the same coverage criteria in determining coverage of all stocks in both research formats. Research on stocks in the Opportunity Research format typically have a higher risk profile, and may offer greater upside.
Since November 2013, Goldman Small Cap Research has been compensated $500 per article by a third party. This article is the opinion of Goldman Small Cap Research and was written based upon publicly available information. The Company has not endorsed or compensated Goldman Small Cap Research for this article. All information contained in these articles was derived from GSCR due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.
Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.
This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.
ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.
For more information, visit our Disclaimer: www.goldmanresearch.com